| Literature DB >> 25417729 |
Lei Zhang1, Hong Yuan, Christina Inscoe, Pavel Chtcheprov, Michael Hadsell, Yueh Lee, Jianping Lu, Sha Chang, Otto Zhou.
Abstract
Microbeam radiation therapy (MRT) is a promising preclinical modality for cancer treatment, with remarkable preferential tumoricidal effects, that is, tumor eradication without damaging normal tissue functions. Significant lifespan extension has been demonstrated in brain tumor-bearing small animals treated with MRT. So far, MRT experiments can only be performed in a few synchrotron facilities around the world. Limited access to MRT facilities prevents this enormously promising radiotherapy technology from reaching the broader biomedical research community and hinders its potential clinical translation. We recently demonstrated, for the first time, the feasibility of generating microbeam radiation in a laboratory environment using a carbon nanotube x-ray source array and performed initial small animal studies with various brain tumor models. This new nanotechnology-enabled microbeam delivery method, although still in its infancy, has shown promise for achieving comparable therapeutic effects to synchrotron MRT and has offered a potential pathway for clinical translation.Entities:
Keywords: U87MG glioma; brain tumor; carbon nanotube; glioblastoma multiforme; image guidance; microbeam radiation therapy; temozolomide; x-ray; γ-H2AX
Mesh:
Year: 2014 PMID: 25417729 PMCID: PMC4260778 DOI: 10.1586/14737140.2014.978293
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN: 1473-7140 Impact factor: 4.512